Polyrizon (NASDAQ:PLRZ) Upgraded to Hold at Wall Street Zen

Polyrizon (NASDAQ:PLRZ) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

Separately, Weiss Ratings lowered shares of Polyrizon from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Polyrizon Stock Performance

Polyrizon stock opened at $12.99 on Friday. The company’s 50-day moving average is $13.75 and its 200-day moving average is $12.37. Polyrizon has a fifty-two week low of $2.88 and a fifty-two week high of $18.20.

Polyrizon (NASDAQ:PLRZ) last released its quarterly earnings data on Saturday, February 14th. The company reported ($2.81) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Polyrizon stock. Jane Street Group LLC bought a new position in shares of Polyrizon Ltd. (NASDAQ:PLRZ) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned approximately 1.35% of Polyrizon as of its most recent SEC filing.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.